Key considerations in the treatment of complicated staphylococcal infections
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinically, VRSA infections severely limit treatment options, as vancomycin has long been a cornerstone therapy for MRSA.”
From Staphylococcus aureus: A Review of the Pathogenesis and Virulence Mechanisms (2025) · cites this paper as [279]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lina, G., Piemont, Y., Godail-Gamot, F., Bes, M., Peter, M.-O., Gauduchon, V., Vandenesch, F., & Etienne, J. (1999) · Clinical Infectious Diseases · doi:10.1086/313461 · Cited by 2,489 · cited 2×
“CA-MRSA strains are also associated with greater toxin production; most strains carry the Panton–Valentine leukocidin genes [16], which encode cytotoxins that can cause tissue necrosis and leukocyte destruction [17].”
BackgroundNaimi, T. S. (2003) · JAMA · doi:10.1001/jama.290.22.2976 · Cited by 1,688
Methicillin-Resistant Staphylococcus aureus Disease in Three Communities
Fridkin, S. K., Hageman, J. C., Morrison, M., Sanza, L. T., Como-Sabetti, K., Jernigan, J. A., Harriman, K., Harrison, L. H., Lynfield, R., & Farley, M. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043252 · Cited by 1,493
Overview of Nosocomial Infections Caused by Gram-Negative Bacilli
Weinstein, R. A., Gaynes, R., Edwards, J. R., & System, N. N. I. S. (2005) · Clinical Infectious Diseases · doi:10.1086/432803 · Cited by 1,404 · cited 3×
“This trend is especially apparent for bloodstream infections, where Gram-positive pathogens can account for up to 70% of infections, and for surgical site infections, where the predominant cause has shifted from Gram-negative bacteria to Gram-positive bacteria over the past 20 years [4].”
BackgroundInfection with Vancomycin-Resistant Staphylococcus aureus Containing the vanA Resistance Gene
Chang, S., Sievert, D. M., Hageman, J. C., Boulton, M. L., Tenover, F. C., Downes, F. P., Shah, S., Rudrik, J. T., Pupp, G. R., Brown, W. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025025 · Cited by 1,095 · cited 1×
“In contrast, the first naturally occurring, definitively VRSA isolate was reported in the USA in June 2002 [36].”
BackgroundGroom, A. V. (2001) · JAMA · doi:10.1001/jama.286.10.1201 · Cited by 360
Research works printed but not linked: 55
- Gonzalez-Romo, 2003, Prevalence and treatment of Gram-positive infections in internal medicine departments of Spanish hospitals: IGP Study, Rev Esp Quimioter, 16, 428
- Bouza, 2001, Infections caused by Gram-positive bacteria: situation and challenges of treatment, Clin Microbiol Infect, 7, iii, 10.1046/j.1469-0691.2001.00064.x · doi:10.1046/j.1469-0691.2001.00064.x
- Lepape, 2003, Epidemiology of Gram-positive infections in France: changing resistance, Presse Med, 32, S5
- Schaberg, 1991, Major trends in the microbial etiology of nosocomial infection, Am J Med, 91, 72S, 10.1016/0002-9343(91)90346-Y · DOI · Paper page
- Wisplinghoff, 2004, Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study, Clin Infect Dis, 39, 309, 10.1086/421946 · DOI · Paper page
- Moet, 2007, Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: Report from the SENTRY Antimicrobial Surveillance Program (1998–2004), Diagn Microbiol Infect Dis, 57, 7, 10.1016/j.diagmicrobio.2006.05.009 · DOI · Paper page
- Finch, 2006, Gram-positive infections: lessons learnt and novel solutions, Clin Microbiol Infect, 12, 3, 10.1111/j.1469-0691.2006.01624.x · DOI
- Jones, 2006, Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains, Clin Infect Dis, 42, S13, 10.1086/491710 · DOI · Paper page
- Whitby, 2001, Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: a meta-analysis, Med J Aust, 175, 264, 10.5694/j.1326-5377.2001.tb143562.x · DOI · Paper page
- Cosgrove, 2003, Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis, Clin Infect Dis, 36, 53, 10.1086/345476 · DOI · Paper page
- Boyle-Vavra, 2007, Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton–Valentine leukocidin, Lab Invest, 87, 3, 10.1038/labinvest.3700501 · DOI · Paper page
- Vandenesch, 2003, Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton–Valentine leukocidin genes: worldwide emergence, Emerg Infect Dis, 9, 978, 10.3201/eid0908.030089 · DOI · Paper page
- Weber, 2005, Community-associated methicillin-resistant Staphylococcus aureus, Clin Infect Dis, 41, S269, 10.1086/430788 · DOI · Paper page
- Beam, 2006, Community-acquired methicillin-resistant Staphylococcus aureus: prevalence and risk factors, J Athl Train, 41, 337
- Friedman, 2002, Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections, Ann Intern Med, 137, 791, 10.7326/0003-4819-137-10-200211190-00007 · DOI · Paper page
- 2001, Methicillin-resistant Staphylococcus aureus skin or soft tissue infections in a state prison—Mississippi 2000, MMWR, 50, 919
- 2003, Methicillin-resistant Staphylococcus aureus infections in correctional facilities—Georgia, California, and Texas, 2001–2003, MMWR, 52, 992
- Begier, 2004, A high-morbidity outbreak of methicillin-resistant Staphylococcus aureus among players on a college football team, facilitated by cosmetic body shaving and turf burns, Clin Infect Dis, 39, 1446, 10.1086/425313 · DOI · Paper page
- Nguyen, 2005, Recurring methicillin-resistant Staphylococcus aureus infections in a football team, Emerg Infect Dis, 11, 526, 10.3201/eid1104.041094 · DOI · Paper page
- 2003, Methicillin-resistant Staphylococcus aureus infections among competitive sports participants—Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000–2003, MMWR, 52, 793
- Zinderman, 2004, Community-acquired methicillin-resistant Staphylococcus aureus among military recruits, Emerg Infect Dis, 10, 941, 10.3201/eid1005.030604 · DOI · Paper page
- Ellis, 2004, Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers, Clin Infect Dis, 39, 971, 10.1086/423965 · DOI · Paper page
- Elston, 2007, Community-acquired methicillin-resistant Staphylococcus aureus, J Am Acad Dermatol, 56, 1, 10.1016/j.jaad.2006.04.018 · DOI · Paper page
- Gemmell, 2006, Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK, J Antimicrob Chemother, 57, 589, 10.1093/jac/dkl017 · DOI · Paper page
- Stevens, 2005, Practice guidelines for the diagnosis and management of skin and soft-tissue infections, Clin Infect Dis, 41, 1373, 10.1086/497143 · DOI · Paper page
- Chang, 2003, Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study, Medicine (Baltimore), 82, 333, 10.1097/01.md.0000091184.93122.09 · DOI · Paper page
- Finch, 2005, Safety and efficacy of glycopeptide antibiotics, J Antimicrob Chemother, 55, ii5, 10.1093/jac/dki004 · DOI
- Appelbaum, 2006, The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus, Clin Microbiol Infect, 12, 16, 10.1111/j.1469-0691.2006.01344.x · DOI · Paper page
- Tenover, 1998, Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides, J Clin Microbiol, 36, 1020, 10.1128/JCM.36.4.1020-1027.1998 · DOI · Paper page
- Flannagan, 2003, Plasmid content of a vancomycin-resistant Enterococcus faecalis isolate from a patient also colonized by Staphylococcus aureus with a VanA phenotype, Antimicrob Agents Chemother, 47, 3954, 10.1128/AAC.47.12.3954-3959.2003 · DOI · Paper page
- Weigel, 2003, Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus, Science, 302, 1569, 10.1126/science.1090956 · DOI · Paper page
- Tenover, 2004, Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania, Antimicrob Agents Chemother, 48, 275, 10.1128/AAC.48.1.275-280.2004 · DOI · Paper page
- Arthur, 1993, Genetics and mechanisms of glycopeptide resistance in enterococci, Antimicrob Agents Chemother, 37, 1563, 10.1128/AAC.37.8.1563 · DOI · Paper page
- Noble, 1992, Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus, FEMS Microbiol Lett, 72, 195, 10.1111/j.1574-6968.1992.tb05089.x · DOI · Paper page
- Bush, 2004, Vancomycin-resistant Staphylococcus aureus in the clinic: not quite armageddon, Clin Infect Dis, 38, 1056, 10.1086/382366 · doi:10.1086/382366
- Wang, 2006, Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period, J Clin Microbiol, 44, 3883, 10.1128/JCM.01388-06 · DOI · Paper page
- Maor, 2007, Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) bacteremia in a tertiary care center, J Clin Microbiol, 45, 1511, 10.1128/JCM.01262-06 · DOI · Paper page
- Walsh, 2002, The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus, Annu Rev Microbiol, 56, 657, 10.1146/annurev.micro.56.012302.160806 · DOI · Paper page
- Sancak, 2005, Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital, J Antimicrob Chemother, 56, 519, 10.1093/jac/dki272 · DOI · Paper page
- Fridkin, 2001, Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know, Clin Infect Dis, 32, 108, 10.1086/317542 · DOI · Paper page
- Tenover, 2007, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus, Clin Infect Dis, 44, 1208, 10.1086/513203 · DOI · Paper page
- Sherris, 1986, Problems in in vitro determination of antibiotic tolerance in clinical isolates, Antimicrob Agents Chemother, 30, 633, 10.1128/AAC.30.5.633 · DOI
- Tuomanen, 1986, Antibiotic tolerance among clinical isolates of bacteria, Antimicrob Agents Chemother, 30, 521, 10.1128/AAC.30.4.521 · DOI · Paper page
- May, 1998, Glycopeptide tolerance in Staphylococcus aureus, J Antimicrob Chemother, 42, 189, 10.1093/jac/42.2.189 · doi:10.1093/jac/42.2.189
- Steinkraus, 2007, Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant Saureus (MRSA) blood isolates from 2001–05, J Antimicrob Chemother, 60, 788, 10.1093/jac/dkm258 · DOI · Paper page
- Hidayat, 2006, High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity, Arch Intern Med, 166, 2138, 10.1001/archinte.166.19.2138 · DOI · Paper page
- Sakoulas, 2004, Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia, J Clin Microbiol, 42, 2398, 10.1128/JCM.42.6.2398-2402.2004 · DOI · Paper page
- Small, 1990, Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users, Antimicrob Agents Chemother, 34, 1227, 10.1128/AAC.34.6.1227 · DOI · Paper page
- Howden, 2004, Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility, Clin Infect Dis, 38, 521, 10.1086/381202 · DOI · Paper page
- Appelbaum, 2006, MRSA—the tip of the iceberg, Clin Microbiol Infect, 12, 3, 10.1111/j.1469-0691.2006.01402.x · DOI · Paper page
- Finch, 2006, Antibiotic resistance—action to promote new technologies: report of an EU Intergovernmental Conference held in Birmingham, UK, 12–13 December 2005, J Antimicrob Chemother, 58, i3, 10.1093/jac/dkl373 · DOI · Paper page
- Alder, 2004, The advantage of bactericidal drugs in the treatment of infection, Curr Infect Dis Rep, 6, 251, 10.1007/s11908-004-0042-1 · DOI
- Pankey, 2004, Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections, Clin Infect Dis, 38, 864, 10.1086/381972 · DOI · Paper page
- Shah, 2005, The need for new therapeutic agents: what is the pipeline, Clin Microbiol Infect, 11, 36, 10.1111/j.1469-0691.2005.01141.x · DOI
- Finberg, 2004, The importance of bactericidal drugs: future directions in infectious disease, Clin Infect Dis, 39, 1314, 10.1086/425009 · DOI · Paper page
Cited by
Staphylococcus aureus: A Review of the Pathogenesis and Virulence Mechanisms
Touaitia, R., Mairi, A., Ibrahim, N. A., Basher, N. S., Idres, T., & Touati, A. (2025) · Antibiotics · doi:10.3390/antibiotics14050470 · Cited by 273
Metadata
- Authors
- Jones, R. N.
- Venue
- Clinical Microbiology and Infection
- Publisher
- Elsevier BV
- Published
- 2008-03
- Volume
- 14
- Pages
- 3-9
- ISSN
- 1198-743X
- Cited by
- 22
- References
- 6
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 2464 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Key considerations in the treatment of complicated staphylococcal infections. https://app.cochat.ai/papers/10.1111/j.1469-0691.2008.01923.x
- The paper
- Jones, R. N. (2008). Key considerations in the treatment of complicated staphylococcal infections. Clinical Microbiology and Infection. https://doi.org/10.1111/j.1469-0691.2008.01923.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.